Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with acute myeloid leukemia (AML).
- People who are receiving a stem cell transplant from a donor (called an allogeneic stem cell transplant) at the hospital running this trial.
- People whose AML does not involve certain specific genetic changes (known as fusion genes) that are routinely tested for in the laboratory — such as AML1::ETO, BCR::ABL1, and several others (confirm with trial site for the full list).
- People for whom genetic sequencing test results (called NGS results) from the time of their original AML diagnosis are available and can be reviewed.
- People whose AML did not involve a genetic change called an NPM1 mutation at the time of first diagnosis.
- People whose AML showed certain gene mutations at the time of first diagnosis — such as mutations in genes like DNMT3A, TET2, ASXL1, SRSF2, or similar genes linked to blood cell changes (confirm with trial site for the full list).
Who may not be able to join:
- People whose genetic mutation profile is not suitable for designing a specialised personalised laboratory test (called digital PCR) that is sensitive enough to detect very small amounts of disease (confirm with trial site).
- People who do not have any measurable genetic markers in their AML that could be tracked over time to monitor whether disease remains or returns.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ya-zhen Qin, Ph.D, Peking University People's Hospital
Phone: +861088324637
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cumulative Incidence of Relapse (CIR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.